(4151) – StreetInsider.com Reports
-
Ardelyx (ARDX) Announces Tenapanor for Hyperphosphatemia Approved in Japan
-
MEI Pharma (MEIP) and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting
-
Kyowa Kirin and MEI Pharma (MEIP) Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin’s Lymphoma in Japan
-
Mereo BioPharma (MREO) Announces Appointment of Dr. Abdul Mullick to Board of Directors
-
Cumberland Pharmaceuticals (CPIX) Announces Key Co-Promotion Agreement with Verity Pharmaceuticals to Expand Support for Sancuso
-
MEI Pharma (MEIP) says FDA informed the companies of its position that a randomized trial is now needed to adequately assess drug efficacy and safety of PI3K inhibitor drug candidates
-
Cumberland Pharmaceuticals (CPIX) Acquires Sancuso From Kyowa Kirin North America
-
MEI Pharma (MEIP) and Kyowa Kirin receive Orphan Drug Designation for Zandelisib for the Treatment of Follicular Lymphoma
-
MEI Pharma (MEIP) and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021
-
MEI Pharma (MEIP), Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress
-
Ardelyx (ARDX) Announces Data Supporting Efficacy and Safety of Tenapanor to be Presented at ASN
-
MEI Pharma (MEIP), Kyowa Kirin Announce Global License, Development and Commercialization Agreement for ME-401
-
Ultragenyx Pharma (RARE), Kyowa Kirin Announce FDA Acceptance and Priority Review Designation of Supplemental Biologics License Application for Crysvita for TIO
-
Ultragenyx Pharma (RARE), Kyowa Kirin Announce Intent to Submit sBLA to U.S. FDA for Crysvita in TIO
-
Kyowa Kirin Buys Back Tivozanib Non-Oncology Rights from AVEO Oncology (AVEO)
-
MEI Pharma (MEIP), Kyowa Hakko Kirin Announce License Agreement to Develop and Commercialize ME-401 in Japan
-
Kyowa Kirin, Ultragenyx (RARE) Announce Crysvita Receives Conditional Marketing Authorisation in Europe for Treatment of X-Linked Hypophosphatemia in Children
Back to 4151 Stock Lookup